(Q38915333)

English

17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

Kyoung-Hee Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

An-Hee Jang

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Chul-Gyu Yoo

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

American Journal of Respiratory Cell and Molecular Biology

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

412-421

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Structure and functions of the 20S and 26S proteasomes

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Regulation and function of NF-kappaB transcription factors in the immune system

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

HSP90 and the chaperoning of cancer

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

A central role for the Hsp90.Cdc37 molecular chaperone module in interleukin-1 receptor-associated-kinase-dependent signaling by toll-like receptors.

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Antimyeloma activity of heat shock protein-90 inhibition.

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

WNT and beta-catenin signalling: diseases and therapies

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2014-0186OC

21 January 2018

Identifiers

10.1165/RCMB.2014-0186OC

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38915333&oldid=1796135900"